Papers
Topics
Authors
Recent
Search
2000 character limit reached

Capturing Cumulative Disease Burden in Chronic Kidney Disease Outcome Trials: Area Under the Curve and Restricted Mean Time in Favor of Treatment Beyond Conventional Time-to-First Analysis

Published 24 Jan 2026 in stat.ME | (2601.17241v1)

Abstract: Chronic kidney disease (CKD) affects millions worldwide and progresses irreversibly through stages culminating in end-stage renal disease (ESRD) and death. Outcome trials in CKD traditionally employ time-to-first-event analyses using the Cox models. However, this approach has fundamental limitations for progressive diseases: it assigns equal weight to each composite endpoint component despite clear clinical hierarchy: an eGFR decline threshold receives the same weight as ESRD or death in the analysis, and it captures only the first occurrence while ignoring subsequent progression. Given CKD's gradual evolution over years, comprehensive treatment evaluation requires quantifying cumulative disease burden: integrating both event severity and time spent in each disease state. We propose two complementary approaches to better characterize treatment benefits by incorporating event severity and state occupancy: area under the curve (AUC) and restricted mean time in favor of treatment (RMT-IF). The AUC method assigns ordinal severity scores to disease states and calculates the area under the mean cumulative score curve, quantifying total event-free time lost. Treatment effects are expressed as AUC ratios or differences. The RMT-IF extends restricted mean survival time to multistate processes, measuring average time patients in the treatment arm spend in more favorable states versus the comparator. These methods better capture CKD's progressive nature where treatment benefits extend beyond first-event delay to overall disease trajectory modification. By discriminating between events of differing clinical importance and quantifying the complete disease course, these estimands offer alternative assessment frameworks for kidney-protective therapies, potentially improving efficiency and interpretability of future CKD outcome trials.

Authors (3)

Summary

No one has generated a summary of this paper yet.

Paper to Video (Beta)

No one has generated a video about this paper yet.

Whiteboard

No one has generated a whiteboard explanation for this paper yet.

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Continue Learning

We haven't generated follow-up questions for this paper yet.

Collections

Sign up for free to add this paper to one or more collections.

Tweets

Sign up for free to view the 2 tweets with 0 likes about this paper.